Faculty profile

Morag Park

ResearcherOncologyUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.

Morag Park

Researcher

Oncology

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
43 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

116

Publications

Citations

h-index

Collaborators

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Associated Fibroblasts Immunotherapy Patient Selection Preclinical Models Triple Negative Breast Cancer Tumor Microenvironment

Latest papers

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.
Cell reports. Medicine · 2026
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.
Cancer treatment reviews · 2026
Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.
Non-coding RNA · 2026

All 116 publications

116 publications.

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.

Taifour T, Gu Y, Massé A, Meng X, Echavez CD, Zuo D, Sanguin-Gendreau V, Blouin A, Graham-Paquin AL, Addie M, Solymoss E, Xiao B, Proud H, Attalla SS, Nam AJ, Papavasiliou V, Kuasne H, Siegel PM, Keyomarsi K, McCaffrey L, Park M, Muller WJ

Cell reports. Medicine2026

DOI: 10.1016/j.xcrm.2026.103050 PMID: 42727582

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Romero JM, Magrill J, Kalashnikov N, Luo YZ, Chen OJ, Busque S, Ma R, Atallah A, Lazaratos AM, Mendelson D, Wilson L, Deshmukh S, Taifour T, Sorin M, Arthur I, Kuasne H, Levett JY, Wang Y, Seufferlein T, Kleger A, Gout J, Michels AK, Brugarolas J, Poshusta ZS, Hogenson TL, Fernandez-Zapico ME, Hamada A, Yagishita S, Kryeziu K, Lothe RA, Nichols A, Barrett JW, Papaccio F, Castillo J, Inoue M, Massfelder T, Lang H, Lindner V, Nilsson J, Dantes Z, Seppanen H, Wells GA, Kim SH, Ittmann MM, Villanueva H, Lerner SP, Sikora AG, Theillet C, Huang DQ, Khuong-Quang DA, Yeung JC, Park M, Siegel PM, Watson IR, Zogopoulos G, Rose AAN, Dankner M

Cancer treatment reviews2026

DOI: 10.1016/j.ctrv.2026.103190 PMID: 42497819

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.

Nobrega M, Kuasne H, Souza MF, Reis MBD, Oliveira LCB, Fuganti PE, Park M, Cólus IMS

Non-coding RNA2026

DOI: 10.3390/ncrna12050033 PMID: 42776739

A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer.

Bahl S, Dogan-Artun N, Nguyen J, Mahmoud H, Ba-Alawi W, Madani Tonekaboni SA, Kang KK, McGuire M, Tobin C, Silvester J, Savage P, Cressot L, Nand A, Feng G, Guilhamon P, Mer AS, Arlidge C, Elliott MJ, Park M, Cescon DW, Haibe-Kains B, Lupien M

Nature communications2026

DOI: 10.1038/s41467-026-76385-8 PMID: 42749733

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.

Ulukan B, Saatci O, Madrigal A, Kim M, Tian W, Soytas M, Mehrjoo Z, Sahin OS, Sreenivas K, Rao CN, Nishimura T, Pillon V, Anoma JS, Hill E, Rak J, McInnes C, Park M, Brimo F, Tanguay S, Russell RC, Najafabadi H, Riazalhosseini Y, Sahin O

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.07.24.739825 PMID: 42582009

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

Aceto G, Liu K, Arabzadeh A, Tsai S, Xue Y, Monast A, Pilon V, Han M, Morin G, Pavlakis K, Fu L, Park M, Foulkes WD, Wang Y, Huang S

Nature communications2026

DOI: 10.1038/s41467-026-74204-8 PMID: 42297809

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

Maritan SM, Karimi E, Dankner M, Hernandez-Corchado A, Yu MW, Annis MG, Aghazadeh Habashi Y, Rezanejad M, Liu B, Koudieh N, Pichette E, Fallah P, Fiset B, Wei Y, Nehme A, Lee CG, Elias JA, Park M, Riazalhosseini Y, Najafabadi H, Petrecca K, Guiot MC, Quail DF, Walsh LA, Siegel PM

JCI insight2026

DOI: 10.1172/jci.insight.199498 PMID: 42171608

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

Guay J, Kuasne H, Chabot C, Bozek K, Majedi Y, Buchanan M, Aguilar-Mahecha A, Bareke E, Ulmer B, Kong T, Yang K, Liao M, Elebute O, Guo R, Monast A, Morin G, Huang S, Park M, Basik M

Cancer research communications2026

DOI: 10.1158/2767-9764.crc-25-0044 PMID: 41973002

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Jiang J, Zhu X, Fu Z, Liao M, Arabzadeh A, Robert F, Monast A, Pilon V, Pavlakis K, Park M, Foulkes WD, Huang S

NPJ precision oncology2026

DOI: 10.1038/s41698-026-01350-z PMID: 41807550

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekeere A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF, Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, Grünewald TGP, Park M, Rheenen JV, Fendt SM

Nature2026

DOI: 10.1038/s41586-026-10202-6 PMID: 41652772

Something wrong or missing on this profile? Suggest a correction

Morag Park

Research

Latest papers

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.

A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer.

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Frequent collaborators

Morag Park

Sidong Huang

ATILLA Omeroglu

Janusz Rak

Anne-Claude Gingras

Kevin Petrecca

Benjamin Haibe-Kains

Kevin Petrecca

Sarkis Meterissian

Elena Kuzmin

Jerry Pelletier

Nahum Sonenberg

Guillaume Bourque

Xiang-Jiao Yang

Alain Nepveu

Yasser Riazalhosseini

Julie St-Pierre

Lorenzo Ferri

Yemin Wang

Mark Basik

Jonathan Spicer

Mark Sorin

Guojun Chen

Ramy Saleh

Julianna Blagih

Arielle Elkrief

Morag Park

Research

Latest papers

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.

A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer.

Lysyl oxidase drives ccRCC progression by coordinating HIF-2&#x3b1; transcription program with tumor microenvironment.

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Frequent collaborators

Morag Park

Sidong Huang

ATILLA Omeroglu

Janusz Rak

Anne-Claude Gingras

Kevin Petrecca

Benjamin Haibe-Kains

Kevin Petrecca

Sarkis Meterissian

Elena Kuzmin

Jerry Pelletier

Nahum Sonenberg

Guillaume Bourque

Xiang-Jiao Yang

Alain Nepveu

Yasser Riazalhosseini

Julie St-Pierre

Lorenzo Ferri

Yemin Wang

Mark Basik

Jonathan Spicer

Mark Sorin

Guojun Chen

Ramy Saleh

Julianna Blagih

Arielle Elkrief

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.